Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: Immunology In Focus As US FDA Approves Kevzara, New Breakthrough Actemra Use; J&J, Sun Advance Psoriasis Candidates

Executive Summary

The latest immunology drug development news and highlights from our FDA Performance Tracker.

You may also be interested in...



Kevzara: Sanofi Caught In Middle Of US FDA Debate On Data Analysis

Agency staff concluded that sarilumab demonstrated less radiographic progression of structural damage in a 52-week trial but disagreed over the statistical method that should be used to show the data in labeling. CDER Director Woodcock made the final call, choosing the method preferred by sponsor Sanofi and long used for other rheumatoid arthritis treatments.

Roche Racks Up Another RoActemra Green Light To Boost Revenues

The Swiss giant's blockbuster is the first non-steroid therapy approved in Europe for giant cell arteritis and the first major advance in treatment for over 50 years.

Actemra CAR-T-Related Indication Comes With Help From Novartis, Kite, US FDA

Genentech's interleukin-6 inhibitor got bonus approval based on data from development programs for Novartis' and Kite's chimeric antigen receptor T-cell therapies; CAR-T developers allowed FDA to access the Actemra-related data in their applications and conduct its own pooled analysis.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM000882

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel